Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments. Increasingly, the choroid is being recognized ...

Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes. From surgical innovations to artificial intelligence ...

Modern Retina November and December 2025 | Modern Retina Digital Edition | Journal | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in ...

Prof Dr Rajvardhan Azad explains how unified guidelines, AI-driven tools, and cross-disciplinary collaboration could transform outcomes for premature infants. As retinopathy of prematurity (ROP) ...

Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation. As artificial intelligence (AI) continues to reshape the ...

The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology. The Health Canada approval was based on a “totality of evidence including ...

According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.Corza Medical has announced the commercial launch of the SensorTek ROP Kit, a single ...

Study finds retinal progenitor cell injections improve outcomes in rat model of diabetic retinopathy ...

Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 ...

Justis Ehlers, MD, FASRS, presented "PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy," during the 2025 ...

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials. OliX Pharmaceuticals, Inc. announced positive results from a phase 1 study of the safety and ...